Evidence map›Paper›PMID 29588542›Full record

ArticleNature microbiology2018

Human cytomegalovirus reprogrammes haematopoietic progenitor cells into immunosuppressive monocytes to achieve latency.

Dihan Zhu, Chaoyun Pan, Jingxue Sheng, Hongwei Liang, Zhen Bian, Yuan Liu, Phong Trang, Jianguo Wu, Fenyong Liu, Chen-Yu Zhang and 1 more

Open access · greenAbstract read
In one paragraph

Article in Nature microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 95 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Human cytomegalovirus and neonatal infection.Current research in microbial sciences · 2024
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Dihan ZhuState Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, Nanjing Advanced Institute for Life Sciences, Nanjing University School of Life Sciences, Nanjing, Jiangsu, China.
Chaoyun PanState Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, Nanjing Advanced Institute for Life Sciences, Nanjing University School of Life Sciences, Nanjing, Jiangsu, China.
Jingxue ShengSchool of Public Health, University of California, Berkeley, CA, USA.
Hongwei LiangState Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, Nanjing Advanced Institute for Life Sciences, Nanjing University School of Life Sciences, Nanjing, Jiangsu, China.
Zhen BianState Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, Nanjing Advanced Institute for Life Sciences, Nanjing University School of Life Sciences, Nanjing, Jiangsu, China.
Yuan LiuCenter for Inflammation, Infection Diseases and Immunology, Georgia State University, Atlanta, GA, USA.
Phong TrangSchool of Public Health, University of California, Berkeley, CA, USA.
Jianguo WuState Key Laboratory of Virology, Wuhan University School of Life Sciences, Wuhan, Hubei, China. jwu@whu.edu.cn.ORCID 0000-0002-8326-2895
Fenyong LiuSchool of Public Health, University of California, Berkeley, CA, USA. liu_fy@berkeley.edu.ORCID 0000-0001-5824-1745
Chen-Yu ZhangState Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, Nanjing Advanced Institute for Life Sciences, Nanjing University School of Life Sciences, Nanjing, Jiangsu, China. cyzhang@nju.edu.cn.ORCID 0000-0002-2942-7257
Ke ZenState Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, Nanjing Advanced Institute for Life Sciences, Nanjing University School of Life Sciences, Nanjing, Jiangsu, China. kzen@nju.edu.cn.ORCID 0000-0002-5166-2974
Georgia State University · USNanjing University · CNBerkeley Public Health Division · USJinan University · CNUniversity of California, Berkeley · USWuhan University · CN

Funding

RIBOZYMES FOR STUDIES AND TREATMENT OF HCMV INFECTIONSR01AI041927 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 1997 to 2012
$3.7M
Cytomegalovirus virulence in immunodeficient hostsR01AI050468 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 2002 to 2013
$3.4M
Persistent infection of human cytomegalovirus in oral mucosaR01DE025462 · NIDCR · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 2015 to 2019
$2.3M
Human cytomegalovirus chromatin modifications in oral infectionR01DE023935 · NIDCR · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 2013 to 2017
$2.3M
NIAID NIH HHS R01 AI041927NIAID NIH HHS R01 AI050468NIDCR NIH HHS R01 DE023935NIDCR NIH HHS R01 DE025462
6 · The paper itself

Abstract

The precise cell type hosting latent human cytomegalovirus (HCMV) remains elusive. Here, we report that HCMV reprogrammes human haematopoietic progenitor cells (HPCs) into a unique monocyte subset to achieve latency. Unlike conventional monocytes, this monocyte subset possesses higher levels of B7-H4, IL-10 and inducible nitric oxide synthase (iNOS), a longer lifespan and strong immunosuppressive capacity. Cell sorting of peripheral blood from latently infected human donors confirms that only this monocyte subset, representing less than 0.1% of peripheral mononuclear cells, is HCMV genome-positive but immediate-early-negative. Mechanistic studies demonstrate that HCMV promotes the differentiation of HPCs into this monocyte subset by activating cellular signal transducer and activator of transcription 3 (STAT3). In turn, this monocyte subset generates a high level of nitric oxide (NO) to silence HCMV immediate-early transcription and promote viral latency. By contrast, the US28-knockout HCMV mutant, which is incapable of activating STAT3, fails to reprogramme the HPCs and achieve latency. Our findings reveal that via activating the STAT3-iNOS-NO axis, HCMV differentiates human HPCs into a longevous, immunosuppressive monocyte subset for viral latency.

Indexed as

Cell DifferentiationCellular ReprogrammingCytomegalovirusHematopoietic Stem CellsHost-Pathogen InteractionsHumansImmune ToleranceInterleukin-10MonocytesNitric OxideNitric Oxide Synthase Type IISTAT3 Transcription FactorVirus LatencyV-Set Domain-Containing T-Cell Activation Inhibitor 1IL10 protein, humanInterleukin-10Nitric OxideNitric Oxide Synthase Type IINOS2 protein, humanSTAT3 protein, humanSTAT3 Transcription FactorV-Set Domain-Containing T-Cell Activation Inhibitor 1VTCN1 protein, human

Identifiers

PMID29588542
PMCPMC6537872
OpenAlexW2796048884

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.